

# Supporting Scotland's life sciences sector government strategy, regulation and preparing for Brexit 22<sup>nd</sup> March 2018

# **CONDITIONS FOR USE OF TRANSCRIPTS:**

This document is intended to provide a timely reference for interested parties who are unable to attend the event to which it refers. Some portions are based on transcripts of proceedings and others consist of text submitted by speakers or authors, and are clearly marked as such. As such, apart from where it is indicated that the text was supplied by the speaker, it has not been possible for the transcript to be checked by speakers and so this portion of the document does not represent a formal record of proceedings. Despite best endeavours by Westminster Forum Projects and its suppliers to ensure accuracy, text based on transcription may contain errors which could alter the intended meaning of any portion of the reported content. Anyone who intends to publicly use or refer to any text based on the transcript should make clear that speakers have not had the opportunity for any corrections, or check first with the speaker in question. If in doubt please contact the forum first.

# **Contents**

| About this Publication  | 3          |
|---|------------|
| <u>Agenda</u>   | 4          |
| Session Chair's opening remarks Kenneth Gibson MSP, Convener, Cross-Party Group on Life Sciences (transcript)   | 6          |
| Policy priorities for Scotland's life sciences sector   |            |
| <b>Paul Wheelhouse MSP</b> , Minister for Business, Innovation and Energy, The Scottish Government (transcript)  Questions and comments from the floor (transcript)                                 | 7<br>11    |
| Next steps for implementation of the Montgomery Review - approving new medicines, funding mechanisms and  |            |
| establishing a national formulary   |            |
| <b>Dr Brian Montgomery</b> , Author, <i>Review of Access to New Medicines</i> ; Independent Healthcare Consultant and former  |            |
| Medical Director and Deputy Chief Executive, NHS Fife (transcript)  | 17         |
| <b>Dr Alan MacDonald</b> , Chairman, Scottish Medicines Consortium (transcript)  Questions and comments from the floor (transcript)   | 20<br>22   |
| Supporting innovation, collaboration, and adoption of new technologies  |            |
| <b>Ken Sutherland</b> , President, Canon Medical Research Europe and Chair, Scottish Life Sciences Association (transcript)   | 28         |
| Jim Miller, Director, Procurement, Commissioning and Facilities, NHS National Services for Scotland (transcript)  | 30         |
| Sandra Auld, Director, Healthcare Public Affairs (transcript)   | 32         |
| <b>Dr Allison Jackson</b> , Executive Director, Scottish Universities Life Sciences Alliance (transcript)   | 34         |
| Carina Healy, Partner, CMS (transcript)   | 36         |
| Questions and comments from the floor (transcript)  | 38         |
| <u>Session Chair's closing remarks</u> <b>Kenneth Gibson MSP</b> , Convener, Cross-Party Group on Life Sciences (transcript)  | 49         |
| Session Chair's opening remarks   |            |
| <b>Dr Brian Montgomery</b> , Author, <i>Review of Access to New Medicines</i> ; Independent Healthcare Consultant and former  |            |
| Medical Director and Deputy Chief Executive, NHS Fife (transcript)  | 50         |
| Supporting internationalisation, building strategic relationships and accessing new markets   |            |
| Julia Brown, Director, Life and Chemical Sciences, Scottish Enterprise (transcript)   | 51         |
| Implications of Brexit for Medicines Regulation  Professor Street Poliston Chair Commission on Human Medicines MUDA (transported)   |            |
| Professor Stuart Ralston, Chair, Commission on Human Medicines, MHRA (transcript)   | 55         |
| Assessing the challenges and opportunities of Brexit for the life sciences sector   |            |
| Alison Culpan, Scotland Director, ABPI (transcript)   | 58         |
| <b>Dr Sarah Hardy</b> , Chief Investment Officer, Archangels ( <i>transcript</i> ) <b>Mark Cook</b> , Director, Reimbursement & Government Affairs, Medtronic UK and Chair, Scotland Working Group, | 60         |
| Association of British Healthcare Industries (transcript)   | 62         |
| Chris Brodie, Lead Head of Skills Planning & Sector Development, Skills Development Scotland (transcript)   | 64         |
| Questions and comments from the floor with <b>Julia Brown</b> , Director, Life and Chemical Sciences, Scottish Enterprise and   |            |
| Professor Stuart Ralston, Chair, Commission on Human Medicines, MHRA (transcript)   | 6 <b>7</b> |
| Session Chair's and Scotland Policy Conferences closing remarks   |            |
| <b>Dr Brian Montgomery</b> , Author, <i>Review of Access to New Medicines</i> ; Independent Healthcare Consultant and former  |            |
| Medical Director and Deputy Chief Executive, NHS Fife (transcript)  | 71         |
| Sean Cudmore, Deputy Editor, Scotland Policy Conferences (transcript)   | 73         |
| List of Delegates Registered for Seminar  | 74         |
| Contributor Biographies   | 78         |

Please be advised that speakers' PowerPoint presentations are included within the transcript itself, just beneath the relevant speaker's text. Please note that not all speakers are able to grant permission for us to include their slides.

# **About this Publication**

This publication reflects proceedings at the Scotland Policy Conferences Keynote Seminar: Supporting Scotland's life sciences sector - government strategy, regulation and preparing for Brexit held on 22<sup>nd</sup> March 2018. The views expressed in the articles are those of the named authors, not those of the Forum or the sponsors, apart from their own articles.

Although Scotland Policy Conferences is grateful to all sponsors for the funding on which we depend, participation in events and publications is never conditional on being a sponsor. As well as funding ongoing operations, sponsorship enables the Forum to distribute complimentary copies of publications, and offer complimentary tickets for events, to Government ministers, parliamentarians and officials most involved in policy.

This publication is copyright. Its copying, in whole or in part, is not permitted without the prior written consent of the publishers. However, extracts of the text may be reproduced for academic or review purposes, subject to the conditions of use outlined in the previous page, providing they are accurate, are not used in a misleading context and the author, their organisation and the Scotland Policy Conferences are acknowledged. We would also appreciate being informed.

## **Scotland Policy Conferences**

UK Headquarters 4 Bracknell Beeches Old Bracknell Lane West Bracknell Berkshire RG12 7BW

T: 01344 864796 F: 01344 420121 publications@westminsterforumprojects.co.uk

### **Directors**

Peter van Gelder Chris Whitehouse